Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
Open accessThe DOI matches its Crossref record; 384 of the 384 references it cites were found in a registry or an index.
Abstract
A panel of experts was convened by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) to update the 2010 clinical practice guideline on Clostridium difficile infection (CDI) in adults. The update, which has incorporated recommendations for children (following the adult recommendations for epidemiology, diagnosis, and treatment), includes significant changes in the management of this infection and reflects the evolving controversy over best methods for diagnosis. Clostridium difficile remains the most important cause of healthcare-associated diarrhea and has become the most commonly identified cause of healthcare-associated infection in adults in the United States. Moreover, C. difficile has established itself as an important community pathogen. Although the prevalence of the epidemic and virulent ribotype 027 strain has declined markedly along with overall CDI rates in parts of Europe, it remains one of the most commonly identified strains in the United States where it causes a sizable minority of CDIs, especially healthcare-associated CDIs. This guideline updates recommendations regarding epidemiology, diagnosis, treatment, infection prevention, and environmental management.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clostridium difficile is a Gram‐positive extracellular pathogen, which remains localized to the gastrointestinal tract but can cause severe toxin‐mediated gastrointestinal pathology, with a mortality rate of up to 6%. 67 , 68”
From The battle for iron in enteric infections (2020) · cites this paper as [68]
Citations
Cites
Multistate point-prevalence survey of health care-associated infections
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306801 · Cited by 3,931
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Stool form scale as a useful guide to intestinal transit time
Lewis, S. J., & Heaton, K. W. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709011203 · Cited by 3,244
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Self-citationBurden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641
Self-citationDethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361
An Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Self-citationLoo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Self-citationGoing from evidence to recommendations
Guyatt, G. H., Oxman, A. D., Kunz, R., Falck-Ytter, Y., Vist, G. E., Liberati, A., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39493.646875.ae · Cited by 1,810
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585
Research works printed but not linked: 3
- Health Protection Agency, 2005, Outbreak of Clostridium difficile infection in a hospital in southeast England, CDR Wkly, 15
- Tleyjeh, 2012, Association between acid-suppression therapy and Clostridium difficile infection: a systematic review and meta-analysis, Clin Microbiol Infect, 18, 113
- Polage, 2015, Overdiagnosis of Clostridium difficile infection in the molecular test era, JAMA Intern Med, 175, 1792, 10.1001/jamainternmed.2015.4114 · DOI · Paper page
Cited by
Items 301–400 of 1,000
Eubank, T. A., Dureja, C., Garey, K. W., Hurdle, J. G., & Gonzales-Luna, A. J. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae087 · Cited by 40
Self-citationThe Current State of Antimicrobial Stewardship: Challenges, Successes, and Future Directions
Emberger, J., Tassone, D., Stevens, M., & Markley, J. D. (2018) · Current Infectious Disease Reports · doi:10.1007/s11908-018-0637-6 · Cited by 41
Sandlund, J., Bartolome, A., Almazan, A., Tam, S., Biscocho, S., Abusali, S., Bishop, J. J., Nolan, N. P., Estis, J., Todd, J. A., et al. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.00908-18 · Cited by 39
“Many laboratories have now implemented algorithms for CDI testing that combine the results of NAATs and EIAs in multiple steps (4, 5).”
BackgroundMethodInfluentialBattat, R. J., Duijvestein, M., Casteele, N. V., Singh, S., Dulai, P. S., Valasek, M. A., Mimms, L. T., McFarland, J., Hester, K. D., Renshaw, M. W., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.11.012 · Cited by 40
Kelly, C. P., Chen, X., Williams, D. N., Xu, H. J., Cuddemi, C., Daugherty, K., Barrett, C. G., Miller, M. A., Foussadier, A., Lantz, A., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz330 · Cited by 39
Self-citationKraft, C. S., Parrott, J. S., Cornish, N. E., Rubinstein, M. L., Weissfeld, A. S., McNult, P., Nachamkin, I., Humphries, R. M., Kirn, T. J., Bard, J. D., et al. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00032-18 · Cited by 56
“mentation of infection control measures to prevent transmission (11).”
BackgroundInfluentialCarlson, T. J., Blasingame, D., Gonzales-Luna, A. J., Alnezary, F. S., & Garey, K. W. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.102142 · Cited by 38
“difficile, and can therefore be used for screening [25, 26], but must be paired with another diagnostic test for diagnosis of CDI..[27] For diagnosis of RT106 specifically, multiple brands of EIA tests were determined to be less sensitive than a commercially available NAAT (n = 16) and GDH/EIA algorithms were less sen…”
BackgroundSelf-citationReigadas, E., Bouza, E., Olmedo, M., Vázquez‐Cuesta, S., Villar-Gómara, L., Alcalá, L., Marín, M., Fernández, S. R., Valerio, M., & Muñóz, P. (2019) · Journal of Hospital Infection · doi:10.1016/j.jhin.2019.12.022 · Cited by 44
Gastrointestinal Microbiome – What We Need to Know in Clinical Practice
Ortigão, R., Pimentel‐Nunes, P., Dinis-Ribeiro, M. J., & Libânio, D. (2020) · GE Portuguese Journal of Gastroenterology · doi:10.1159/000505036 · Cited by 46
Epidemiology and Risk Factors for Community Associated Clostridioides difficile in Children
Miranda-Katz, M., Parmar, D. D., Dang, R., Alabaster, A. L., & Greenhow, T. L. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2020.02.005 · Cited by 39
Management of Clostridioides difficile infection in patients with inflammatory bowel disease
Khanna, S. (2020) · Intestinal Research · doi:10.5217/ir.2020.00045 · Cited by 44
“Management of Recurrent CDI For a first recurrence, antibiotic treatment options include a course of fidaxomicin 200 mg twice a day for 10 days or a fidaxomicin EXTEND regimen or a vancomycin 7-week taper regimen, if a standard course of vancomycin was used for the first episode.(6) If fidaxomicin was used for an init…”
BackgroundMethodInfluentialKunishima, H., Ohge, H., Suzuki, H., Nakamura, A., Matsumoto, K., Mikamo, H., Mori, N., Morinaga, Y., Yanagihara, K., Yamagishi, Y., et al. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.12.011 · Cited by 48
Jose, S., Mukherjee, A., Horrigan, O., Setchell, K. D. R., Zhang, W., Moreno‐Fernandez, M. E., Andersen, H. M., Sharma, D., Haslam, D. B., Divanovic, S., et al. (2020) · Mucosal Immunology · doi:10.1038/s41385-020-00338-7 · Cited by 40
Clinical Practice Guidelines for Fecal Microbiota Transplantation in Korea
Gweon, T., Lee, Y. J., Kim, K. O., Yim, S. K., Soh, J. S., Kim, S. Y., Park, J. J., Shin, S. Y., Lee, T. H., Choi, C. H., et al. (2022) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm21221 · Cited by 41
de Chambrun, G. P., Nachury, M., Funakoshi, N., Gérard, R., Bismuth, M., Valats, J.-C., Panaro, F., Navarro, F., Desreumaux, P., Pariente, B., et al. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001223 · Cited by 44
Appaneal, H. J., Caffrey, A. R., & LaPlante, K. L. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1077 · Cited by 41
Fernández, S. G., Frentrup, M., Steglich, M., Gonzaga, A., Cobo, M., López‐Fresneña, N., Cobo, J., Morosini, M.-I., Cantón, R., del Campo, R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43464-4 · Cited by 41
Thorpe, C. M., McDermott, L. A., Tran, M. K., Chang, J. H., Jenkins, S. G., Goldstein, E. J. C., Patel, R., Forbes, B. A., Johnson, S., Gerding, D. N., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00391-19 · Cited by 38
Self-citationTilmanne, A., Martiny, D., Quach, C., Wautier, M., Vandenberg, O., Lepage, P., & Hallin, M. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.07.021 · Cited by 42
Immune Profiling To Predict Outcome of Clostridioides difficile Infection
Abhyankar, M. M., Ma, J. Z., Scully, K. W., Nafziger, A. J., Frisbee, A. L., Saleh, M. M., Madden, G. R., Hays, A. R., Poulter, M., & Petri, W. A. (2020) · mBio · doi:10.1128/mbio.00905-20 · Cited by 38
Worley, J. N., Delaney, M. L., Cummins, C. K., DuBois, A. M., Klompas, M., & Bry, L. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa894 · Cited by 41
Goeser, F., Sifft, B., Stein‐Thoeringer, C. K., Farowski, F., Strassburg, C. P., Brossart, P., Higgins, P. G., Scheid, C., Wolf, D. G. F., Holderried, T. A. W., et al. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13642 · Cited by 39
Dilnessa, T., Getaneh, A., Hailu, W., Moges, F., & Gelaw, B. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262597 · Cited by 38
“difficile infection and numerous novel antiCDI antibiotics are in clinical trials [23].”
BackgroundCore Elements for Implementing Antimicrobial Stewardship Programs in Korean General Hospitals
Cheong, H. S., Park, K. H., Kim, H. B., Kim, S., Kim, B., Moon, C., Lee, M. S., Yoon, Y. K., Jeong, S. J., Kim, Y. C., et al. (2022) · Infection and Chemotherapy · doi:10.3947/ic.2022.0171 · Cited by 43
Diarrhea during critical illness: a multicenter cohort study
Dionne, J. C., Mbuagbaw, L. C. E., Devlin, J. W., Duprey, M. S., Cartin‐Ceba, R., Tsang, J. L. Y., Sullivan, K., Muscedere, J., Alshahrani, M. S. S., Szczeklik, W., et al. (2022) · Intensive Care Medicine · doi:10.1007/s00134-022-06663-8 · Cited by 40
Mayer, S., BONHAG, C. M., Jenkins, P., Cornett, B., Watts, P. J., & Scherbak, D. (2023) · Critical Care Medicine · doi:10.1097/ccm.0000000000005953 · Cited by 40
“…are thought to be useful in a variety of gastrointestinal disorders including antibiotic-associated diarrhea (1, 2, 6), irritable bowel syndrome (10–13), prevention and treatment of C. difficile infection (5, 7), patients receiving nutritional support (14), and inflammatory bowel disease (15).”
The gut microbiome dysbiosis and regulation by fecal microbiota transplantation: umbrella review
Zhang, X., Luo, X., Liang, T. G., Yue, P., Li, M., Liu, K., Zhu, D., Huang, C., Shi, Q., Yang, L., et al. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1286429 · Cited by 45
Caldarelli, M., Rio, P., Marrone, A., Giambra, V., Gasbarrini, A., Gambassi, G., & Cianci, R. (2024) · Biomedicines · doi:10.3390/biomedicines12081716 · Cited by 48
Xu, X., Godoy‐Ruiz, R., Adipietro, K. A., Peralta, C., Ben-Hail, D., Varney, K. M., Cook, M. E., Roth, B. M., Wilder, P. T., Cleveland, T. E., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1919490117 · Cited by 37
Colonic transendoscopic tube-delivered enteral therapy (with video): a prospective study
Zhang, T., Long, C., Cui, B., Buch, H., Wen, Q., Li, Q., Ding, X., Ji, G., & Zhang, F. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01285-0 · Cited by 37
“The colonic route showed higher efficacy than the midgut delivery in CDI [29].”
BackgroundInfluentialPession, A., Zama, D., Muratore, E., Leardini, D., Gori, D., Guaraldi, F., Prete, A., Turroni, S., Brigidi, P., & Masetti, R. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020100 · Cited by 42
Hirano, R., Sakanaka, M., Yoshimi, K., Sugimoto, N., Eguchi, S., Yamauchi, Y., Nara, M., Maeda, S., Ami, Y., Gotoh, A., et al. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1973835 · Cited by 41
“difficile-related infection, the administration of metronidazole, fidaxomicin, or vancomycin has been used but often results in recurrent infections.(10) Recently, fecal microbiota transplantation, the instillation of processed stool collected from a healthy donor into the intestinal tract of patients, has been recomm…”
BackgroundInfluentialBeyond the approved: target sites and inhibitors of bacterial RNA polymerase from bacteria and fungi
Kirsch, S. H., Haeckl, F. P. J., & Müller, R. (2022) · Natural Product Reports · doi:10.1039/d1np00067e · Cited by 39
Viprey, V. F., Granata, G., Vendrik, K. E. W., Davis, G. L., Petrosillo, N., Kuijper, E. J., Vilken, T., Lammens, C., Schotsman, J., Benson, A. D., et al. (2022) · Journal of Hospital Infection · doi:10.1016/j.jhin.2022.11.011 · Cited by 48
Self-citationGut microbiota in acute leukemia: Current evidence and future directions
Zhou, Y., Zhou, C., & Zhang, A. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1045497 · Cited by 40
Clostridioides difficile Infection: Diagnosis and Treatment Challenges
Markantonis, J., Fallon, J. T., Madan, R., & Alam, M. Z. (2024) · Pathogens · doi:10.3390/pathogens13020118 · Cited by 52
Kucharzik, T. F., Dignass, A. U., Atreya, R. N., Bokemeyer, B., Esters, P., Herrlinger, K. R., Kannengießer, K., Kienle, P., Langhorst, J., Lügering, A., et al. (2024) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2271-0994 · Cited by 57
Human intestinal microbiome: Role in health and disease
Cantón, R., Ramos, P. D. L., Botella, A. G., García‐Lledó, A., Hernández‐Sampelayo, T., Gómez‐Pavón, J., del Castillo, J. M. G., Martín-Delgado, M. C., Martín‐Sánchez, F. J., Martínez‐Sellés, M., et al. (2024) · Revista Española de Quimioterapia · doi:10.37201/req/056.2024 · Cited by 40
Li, X., Gao, X., Hu, H., Xiao, Y., Li, D., Yu, G., Yu, D., Zhang, T., & Wang, Y. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02622 · Cited by 41
Diagnostic stewardship of C. difficile testing: a quasi-experimental antimicrobial stewardship study
Christensen, A. B., Barr, V. O., Martin, D. W., Anderson, M., Gibson, A. K., Hoff, B. M., Sutton, S. H., Widmaier, V., Salim, A. A., Silkaitis, C., et al. (2019) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2018.336 · Cited by 36
L’Huillier, A. G., Ferreira, V. H., Ku, T., Bahinskaya, I., Kumar, D., & Humar, A. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15371 · Cited by 38
Antigen-Specific Mucosal Immunity Regulates Development of Intestinal Bacteria-Mediated Diseases
Fujimoto, K., Kawaguchi, Y., Shimohigoshi, M., Gotoh, Y., Nakano, Y., Usui, Y., Hayashi, T., Kimura, Y., Uematsu, M., Yamamoto, T., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.08.021 · Cited by 43
Lei, D. K., Ollech, J. E., Andersen, M. J., Weisshof, R., Zmeter, N., Sossenheimer, P. H., & Rubin, D. T. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000460 · Cited by 37
The Microbiota in Hematologic Malignancies
Song, Y., Himmel, B., Öhrmalm, L., & Gyarmati, P. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0693-7 · Cited by 38
Guidelines for Clostridium difficile infection in adults
Kukla, M., Adrych, K., Dobrowolska, A., Mach, T., Reguła, J., & Rydzewska, G. M. (2020) · Gastroenterology Review · doi:10.5114/pg.2020.93629 · Cited by 42
Gut Microbiota Modulation: Implications for Infection Control and Antimicrobial Stewardship
Tan, G. S. E., Tay, H. L., Tan, S. H., Lee, T. H., Ng, T. M., & Lye, D. C. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01458-z · Cited by 41
Fecal microbiota transplantation alters the susceptibility of obese rats to type 2 diabetes mellitus
Zhang, L., Zhou, W., Zhan, L., Hou, S., Zhao, C., Bi, T., & Lu, X. (2020) · Aging · doi:10.18632/aging.103756 · Cited by 43
Gonzales-Luna, A. J., Olaitan, A. O., Shen, W., Deshpande, A., Carlson, T. J., Dotson, K. M., Lancaster, C. K., Begum, K., Alam, M. J., Hurdle, J. G., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab365 · Cited by 36
“CDI severity was assigned as defined by the 2017 Infectious Diseases Society of America and Society for Healthcare Epidemiology of America CDI guideline and utilizing hemodynamic instability, white blood cell count, and serum creatinine values collected within 24 hours of diagnostic stool specimen collection [6].”
BackgroundMethodSelf-citationYu, H., Alfred, T., Nguyen, J. L., Zhou, J., & Olsen, M. A. A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac467 · Cited by 36
Fecal Microbiota Transplantation for Treatment of Acute Graft-versus-Host Disease
Shouval, R., Geva, M., Nagler, A., & Youngster, I. (2019) · Clinical Hematology International · doi:10.2991/chi.d.190316.002 · Cited by 38
Fecal Microbiota Transplantation for the Critically Ill Patient
Limketkai, B. N., Hendler, S., Ting, P., & Parian, A. M. (2018) · Nutrition in Clinical Practice · doi:10.1002/ncp.10228 · Cited by 40
Inpatient Management of Inflammatory Bowel Disease-Related Complications
Kaur, M., Dalal, R. L., Shaffer, S. R., Schwartz, D. A., & Rubin, D. T. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.12.040 · Cited by 35
Parnell, J. M., Fazili, I., Bloch, S. C., Lacy, D. B., Garcia-Lopez, V. A., Bernard, R., Skaar, E. P., Edwards, K. M., & Nicholson, M. R. (2020) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002944 · Cited by 35
Leslie, J. L., Jenior, M. L., Vendrov, K. C., Standke, A. K., Barron, M. R., O’Brien, T. J., Unverdorben, L. V., Thaprawat, P., Bergin, I. L., Schloss, P. D., et al. (2021) · mBio · doi:10.1128/mbio.00522-21 · Cited by 36
“treatment for acute CDI is the antibiotic vancomycin (5).”
BackgroundCao, Y., Wang, L., Ke, S., Villafuerte-Gálvez, J., Pollock, N. R., Barrett, C. G., Sprague, R., Daugherty, K., Xu, H. J., Lin, Q., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.02.069 · Cited by 41
Self-citationAntibiotic Resistance and Biofilm Production Capacity in Clostridioides difficile
Rahmoun, L. A., Azrad, M., & Peretz, A. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.683464 · Cited by 35
Microbiota-directed biotherapeutics: considerations for quality and functional assessment
Fekete, E. E. F., Figeys, D., & Zhang, X. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2186671 · Cited by 38
Klingensmith, N. J., & Coopersmith, C. M. (2023) · Surgical Infections · doi:10.1089/sur.2022.420 · Cited by 37
Prosty, C. J., Hanula, R., Katergi, K., Longtin, Y., McDonald, E. G., & Lee, T. C. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad523 · Cited by 38
Nooij, S., Vendrik, K. E. W., Zwittink, R. D., Ducarmon, Q. R., Keller, J. J., Kuijper, E. J., Terveer, E. M., & on behalf of the Netherlands Donor Feces Bank study group (2024) · Genome Medicine · doi:10.1186/s13073-024-01306-7 · Cited by 41
Chatedaki, C., Voulgaridi, I., Kachrimanidou, M., Hrabák, J., Papagiannitsis, C. C., & Petinaki, E. (2018) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2018.09.009 · Cited by 34
Clostridium difficile colitis: CT findings and differential diagnosis
Guerri, S., Danti, G., Frezzetti, G., Lucarelli, E., Pradella, S., & Miele, V. (2019) · La radiologia medica · doi:10.1007/s11547-019-01066-0 · Cited by 40
The Role of Diagnostic Stewardship in Clostridioides difficile Testing: Challenges and Opportunities
Boly, F., Reske, K. A., & Kwon, J. H. (2020) · Current Infectious Disease Reports · doi:10.1007/s11908-020-0715-4 · Cited by 34
Fecal Microbiota Transplantation for Recurrent Clostridioides difficile infection: The COVID-19 Era
Khanna, S., & Pardi, D. S. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000689 · Cited by 35
“AN APPROACH TOMANAGING RECURRENT CDI IN THE COVID-19 ERA Despite antibiotic treatment after a primary infection, the risk of recurrent CDI is 20%–30%; after a second infection, the risk of recurrence is 40%–50%; and after a third infection, the risk of recurrence over 60% after antibiotics are stopped (1).”
BackgroundCardemil, C. V., Balachandran, N., Kambhampati, A. K., Grytdal, S., Dahl, R. M., Rodriguez‐Barradas, M. C., Vargas, B., Beenhouwer, D. O., Evangelista, K. V., Marconi, V. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa806 · Cited by 34
Fecal microbiota transplantation for recurrent Clostridioides difficile , safety, and pitfalls
Sandhu, A., & Chopra, T. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211053105 · Cited by 41
Wolfhagen, N., Boldingh, Q. J. J., de Lange, M., Boermeester, M. A., & de Jonge, S. W. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005436 · Cited by 35
Yeh, Y., Cheng, H., Le, P., Chen, C.-C., Kuo, C., Chen, C., Chiu, C., & Chiu, C. (2021) · Biomedical Journal · doi:10.1016/j.bj.2021.06.001 · Cited by 33
Emerging Options for the Prevention and Management of Clostridioides difficile Infection
Gonzales-Luna, A. J., Carlson, T. J., & Garey, K. W. (2023) · Drugs · doi:10.1007/s40265-022-01832-x · Cited by 36
Self-citationKhaledi, M., Poureslamfar, B., Alsaab, H. O., Tafaghodi, S., Hjazi, A. M., Singh, R., Alawadi, A. H., Alsaalamy, A. H., Qasim, Q. A., & Sameni, F. (2024) · Annals of Microbiology · doi:10.1186/s13213-023-01744-5 · Cited by 59
“For patients who have experienced several recurrences of C. difficile infection and have not responded to proper antibiotic treatment, current clinical recommendations from the United States advise FMT (L. C. McDonald et al. 2018).”
BackgroundChang, T., Hsu, W.-Y., Yang, T.-I., Lu, C., Hsueh, P., Chen, J., Lee, P., Huang, L., & Chang, L. (2018) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2018.09.002 · Cited by 33
Gentry, C. A., Nguyen, P. K., Thind, S., Kurdgelashvili, G., Skrepnek, G. H., & Williams, R. J. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.12.007 · Cited by 33
Clostridium difficile isolated from faecal samples in patients with ulcerative colitis
Shoaei, P., Shojaei, H., Jalali, M., Khorvash, F., Hosseini, S. M., Ataei, B., Vakili, B., Ebrahimi, F., Tavakoli, H., Esfandiari, Z., et al. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-3965-8 · Cited by 33
Catho, G., & Huttner, B. D. (2019) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2019.1645007 · Cited by 35
Nonalcoholic fatty liver disease as a risk factor for Clostridioides difficile infection
Papić, N., Jelovčić, F., Karlović, M., Marić, L. S., & Vince, A. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03759-w · Cited by 33
Cho, J. M., Cunningham, S. A., Pu, M., Lennon, R. J., Higano, J. D., Jeraldo, P., Sampathkumar, P., Shannon, S. K., Kashyap, P., & Patel, R. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa159 · Cited by 33
The Route to Palatable Fecal Microbiota Transplantation
Fadda, H. M. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-1637-z · Cited by 37
“In 2018, the Infectious Diseases Society of America (IDSA) recommends FMT for patients with two or more recurrences of CDI (44).”
BackgroundPiątek, J., Krauss, H., Ciechelska-Rybarczyk, A., Bernatek, M., Wojtyła-Buciora, P., & Sommermeyer, H. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17093332 · Cited by 38
“considered for therapy: metronidazole, vancomycin and fidaxomicin [38].”
BackgroundWombwell, E., Patterson, M. E., Bransteitter, B. A., & Gillen, L. R. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa808 · Cited by 33
Antimicrobial resistance surveillance of Clostridioides difficile in Australia, 2015–18
Putsathit, P., Hong, S., George, N., Hemphill, C., Huntington, P. G., Korman, T. M., Kotsanas, D., Lahra, M. M., McDougall, R. J., McGlinchey, A., et al. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab099 · Cited by 34
Viral Acute Gastroenteritis in Special Populations
Meier, J. L. (2021) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2021.02.003 · Cited by 41
Song, Y., Yang, D. Y., van Zanten, S. V., Wong, K., McArthur, E., Song, C. Z., Ianiro, G., Cammarota, G., Kelly, C. R., Fischer, M., et al. (2021) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwab023 · Cited by 46
“The IDSA CDI management guidelines recommend highdose oral vancomycin 500 mg four times daily, metronidazole 500 mg intravenously every 8 hours and vancomycin 500 mg four times daily per rectum for SFCDI with early surgical consultation (5).”
BackgroundInfluentialSelf-citationProton Pump Inhibitors, Kidney Damage, and Mortality: An Updated Narrative Review
Edinoff, A. N., Wu, N. W., Parker, K., Dudossat, E., Linquest, L., Flanagan, C. J., Dharani, A., Patel, H., Willett, O., Cornett, E. M., et al. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02476-3 · Cited by 37
“survive in this less acidic environment and propagate infection [37]”
BackgroundGonzales-Luna, A. J., Carlson, T. J., & Garey, K. W. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad642 · Cited by 39
Self-citationLi, H., Li, W., Zhang, W., Yu, S., Liu, Z., Zhang, X., Wu, Y., & Lu, J. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.102094 · Cited by 32
Shaeer, K. M., Chahine, E. B., Gupta, S. V., & Cho, J. C. (2019) · Pharmacy · doi:10.3390/pharmacy7030135 · Cited by 39
Wang, Y., Schluger, A., Li, J., Gomez‐Simmonds, A., Salmasian, H., & Freedberg, D. E. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1115 · Cited by 32
Barker, A., Scaria, E., Safdar, N., & Alagöz, O. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.12522 · Cited by 37
Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection
Chen, J., Gong, C. L., Hitchcock, M. M., Holubar, M. K., Deresinski, S. C., & Hay, J. W. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.04.004 · Cited by 36
The interplay of Clostridioides difficile infection and inflammatory bowel disease
Sehgal, K., Yadav, D., & Khanna, S. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211020285 · Cited by 33
(2019) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-019-02959-1 · Cited by 35
The Rise, Fall, and Rethink of (Fluoro)quinolones: A Quick Rundown
Rodrigues, C. F., & Silva, F. A. M. (2025) · Pathogens · doi:10.3390/pathogens14060525 · Cited by 43
Assa, A., Aloi, M., Biervliet, S. V., Bronský, J., de Carpi, J. M., Gasparetto, M., Gianolio, L., Gordon, H., Hojsak, I., Hudson, A. S., et al. (2025) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.70096 · Cited by 35
Azimirad, M., Krůtová, M., Balaii, H., Kodori, M., Shahrokh, S., Azizi, O., Yadegar, A., Aghdaei, H. A., & Zali, M. R. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.102113 · Cited by 35
Collaborative Antimicrobial Stewardship
Palavecino, E. L., Williamson, J., & Ohl, C. A. (2019) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2019.10.006 · Cited by 32
Kachrimanidou, M., Baktash, A., Metallidis, S., Tsachouridou, Ο., Netsika, F., Dimoglou, D., Kassomenaki, A., Mouza, E., Haritonidou, M., & Kuijper, E. J. (2020) · Anaerobe · doi:10.1016/j.anaerobe.2020.102252 · Cited by 31
Anjewierden, S., Han, Z., Brown, A. M., Donskey, C. J., & Deshpande, A. (2020) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2020.1236 · Cited by 33
Tariq, R., Hayat, M., Pardi, D. S., & Khanna, S. (2021) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-021-04163-z · Cited by 31
The Interplay of SARS-CoV-2 and Clostridioides Difficile Infection
Khanna, S., & Kraft, C. S. (2021) · Future Microbiology · doi:10.2217/fmb-2020-0275 · Cited by 33
Abdrabou, A. M. M., Bajwa, Z. U. H., Halfmann, A., Mellmann, A., Nimmesgern, A., Margardt, L., Bischoff, M., von Müller, L., Gärtner, B. C., & Berger, F. K. (2021) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2021.151507 · Cited by 31
Metadata
- Authors
- McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., Loo, V., Shaklee Sammons, J., Sandora, T. J., & Wilcox, M. H.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Edward Hines, Jr. VA Hospital (US)
- Loyola University Medical Center (US)
- St. Luke's Hospital (US)
- Johns Hopkins University (US)
- Children's Hospital of Philadelphia (US)
- Washington University in St. Louis (US)
- University of Houston (US)
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
- McGill University Health Centre (CA)
- Children’s Hospital of Philadelphia, Pennsylvania
- Boston Children's Hospital (US)
- Leeds Teaching Hospitals NHS Trust (GB)
- Corresponding author
- McDonald, L Clifford
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-02-15
- Volume
- 66
- Issue
- 7
- Pages
- e1-e48
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC6018983
- OpenAlex
- W2791326569
- Cited by
- 2,690
- References
- 383
- Citations by year
- 2026: 148 · 2025: 179 · 2024: 215 · 2023: 305 · 2022: 331 · 2021: 423 · 2020: 486 · 2019: 408 · 2018: 185
- FWCI
- 228.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- Funders
- Agency for Health Research and Quality
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Keywords
- Clostridium difficile infection, nosocomial infections, healthcare-associated diarrhea, pediatric infection, diagnosis, treatment, infection control, environmental management, ribotype 027, community-acquired infections, epidemiology
- MeSH terms
- Adult, Child, Clostridium Infections, Diarrhea, Humans, Retrospective Studies, Societies, Societies, Medical, Clostridioides difficile, Infectious Disease Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.